We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMEA Gives Biosimilars Manufacturers Development Recommendations
EMEA Gives Biosimilars Manufacturers Development Recommendations
May 18, 2009
Companies that plan to make biosimilar drugs to compete with Sanofi-Aventis’ blockbuster blood-clot treatment Lovenox have received a European Medicines Agency (EMEA) guideline for products containing low-molecular-weight heparins (LMWHs).
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor